Dennis Adeegbe, Ph.D.
H. Lee Moffitt Cancer Center & Research Institute
HDAC6 Inhibition and Treg-targeting as Immunotherapeutic Strategy for NSCLC
Lung Cancer Discovery Award
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the United States and treatments that yield durable effects in the greater proportion of patients are still lacking. We recently found that a drug (ACY241) when administered promoted positive quantitative and qualitative changes in the immune cells within the tumors. In follow up studies, we seek to understand how this drug evokes these changes as better understanding of this is important for determining how it can be best used for therapeutic purposes. Another goal of this project is to determine if leveraging the immune-enhancing activity of this drug will be broadly therapeutic than existing treatments if it is combined with drugs that impair the activity of immune-suppressive T cells. These studies have important implications for patients' health in that any observed therapeutic effects beyond existing treatments could pave way for new strategies to combat lung cancer.
Sign up for the latest lung health news sent right to your inbox.
Join more than 500,000 people who receive research updates, inspiring stories, health information and more.